| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6247682 | Transplantation Proceedings | 2014 | 6 Pages |
Abstract
Patients receiving liver transplantation for HCC with a high risk of tumor recurrence may well benefit from everolimus-based immunosuppression, with no added risks of rejection or other post-transplant complications.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
A.O. Ferreiro, M.A. Vazquez-Millán, F.S. López, M.G. Gutiérrez, S.P. Diaz, M.J.L. Patiño,